Safwan M, Bourgleh MS, Haider KH. Clinical experience with cryopreserved mesenchymal stem cells for cardiovascular applications: A systematic review. World J Stem Cells 2025; 17(3): 102067 [DOI: 10.4252/wjsc.v17.i3.102067]
Corresponding Author of This Article
Khawaja Husnain Haider, PhD, Professor, Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box 777, Al Bukairiyah 51941, AlQaseem, Saudi Arabia. kh.haider@sr.edu.sa
Research Domain of This Article
Cell & Tissue Engineering
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Moaz Safwan, Mariam Safwan Bourgleh, Khawaja Husnain Haider, Department of Basic Sciences, Sulaiman Al Rajhi University, Al Bukairiyah 51941, AlQaseem, Saudi Arabia
Author contributions: Haider KH designed and produced the study and its methodology; Safwan M and Bourgleh MS performed database research and screened the extracted records against eligibility criteria, performed the data extraction and plotted and validated the extracted data, performed the quality assessment of the included trials, and conducted the statistical analysis; Safwan M and Haider KH drafted the first manuscript; Safwan M, Bourgleh MS, and Haider KH reviewed the final manuscript; and all the authors contributed to the final manuscript. All authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Khawaja Husnain Haider, PhD, Professor, Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box 777, Al Bukairiyah 51941, AlQaseem, Saudi Arabia. kh.haider@sr.edu.sa
Received: October 7, 2024 Revised: January 17, 2025 Accepted: February 24, 2025 Published online: March 26, 2025 Processing time: 164 Days and 14.8 Hours
Core Tip
Core Tip: Our study yields significant findings that are crucial for regenerative medicine and cardiology. Our findings revealed that cryopreserved mesenchymal stem cells (CryoMSCs) treatment, compared to the control group, resulted in a 2.11% improvement in left ventricular ejection fraction during six months of follow-up, offering hope for potential future therapies. Left ventricular ejection fraction improvement was higher when using umbilical cord-derived mesenchymal stem cells or CryoMSCs with more than 80% post-thaw viability. The CryoMSCs treatment was safe, as there was no significant difference in the incidence of major cardiac adverse events compared to the control group. In addition, no significant effects on mortality and readmission were observed in the CryoMSCs group compared to the control group.
